$VYNE
VYNE Therapeutics Inc. Stock $vyne

$vyne Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000162828018006412 Filed on May 09, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q4
Revenue	$10.14M	$497.0K	$2.775M
YoY Change	2159.02%	10.69%	516.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.090M	$2.700M	$1.710M
YoY Change	155.37%	167.33%	31.54%
% of Gross Profit
Research & Development	$16.23M	$11.02M	$10.55M
YoY Change	197.18%	120.75%	158.58%
% of Gross Profit
Depreciation & Amortization	$0.00	$10.00K	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$19.32M	$13.72M	$12.25M
YoY Change	189.42%	128.46%	127.99%
Operating Profit	-$9.173M	-$13.22M
YoY Change		137.98%
Interest Expense	$826.0K	$563.0K	$200.0K
YoY Change	1047.22%	595.06%	127.27%
% of Operating Profit
Other Income/Expense, Net	$826.0K	$563.0K
YoY Change
Pretax Income	-$8.350M	-$12.66M	-$9.280M
YoY Change	35.77%	131.44%	91.74%
Income Tax			-$7.000M
% Of Pretax Income
Net Earnings	-$8.347M	-$12.66M	-$9.277M
YoY Change	35.66%	131.22%	91.83%
Net Earnings / Revenue	-82.29%	-2546.68%	-334.31%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.460M	-$2.877M	-$1.421M
COMMON SHARES
Basic Shares Outstanding	22.98M shares	22.98M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$153.8M	$155.8M	$59.50M
YoY Change	391.37%
Cash & Equivalents	$73.58M	$78.53M	$10.21M
Short-Term Investments	$80.20M	$77.30M	$49.30M
Other Short-Term Assets	$2.300M	$3.600M	$3.600M
YoY Change	228.57%
Inventory
Prepaid Expenses
Receivables	$93.00K	$234.0K	$786.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$156.2M	$159.7M	$63.86M
YoY Change	388.13%		102.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$25.00K	$28.00K
YoY Change			3.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$10.40M	$20.70M	$3.000M
YoY Change	131.11%
Other Assets	$306.0K	$83.00K	$0.00
YoY Change
Total Long-Term Assets	$10.70M	$20.82M	$3.006M
YoY Change	132.61%		-71.41%
TOTAL ASSETS
Total Short-Term Assets	$156.2M	$159.7M	$63.86M
Total Long-Term Assets	$10.70M	$20.82M	$3.006M
Total Assets	$166.9M	$180.5M	$66.87M
YoY Change	356.01%		59.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.100M	$3.501M	$2.462M
YoY Change	155.0%		61.34%
Accrued Expenses	$3.300M	$3.174M	$3.559M
YoY Change	120.0%		512.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.600M	$8.471M	$7.817M
YoY Change	-16.5%		100.28%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.0K	$20.00K	$22.00K
YoY Change	-98.7%		-61.4%
Total Long-Term Liabilities	$100.0K	$20.00K	$22.00K
YoY Change	-98.7%		-61.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.600M	$8.471M	$7.817M
Total Long-Term Liabilities	$100.0K	$20.00K	$22.00K
Total Liabilities	$8.700M	$14.78M	$14.57M
YoY Change	-51.67%		16.68%
SHAREHOLDERS EQUITY
Retained Earnings		-$71.85M	-$59.19M
YoY Change			96.55%
Common Stock		$3.000K	$2.208M
YoY Change			220700.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$158.2M	$165.7M	$68.60M
YoY Change
Total Liabilities & Shareholders Equity	$166.9M	$180.5M	$66.87M
YoY Change	356.01%		59.01%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q4
OPERATING ACTIVITIES
Net Income	-$8.347M	-$12.66M	-$9.277M
YoY Change	35.66%	131.22%	91.83%
Depreciation, Depletion And Amortization	$0.00	$10.00K	$0.00
YoY Change
Cash From Operating Activities	-$12.65M	-$11.20M	-$10.17M
YoY Change	-42266.67%	100.61%	124.5%
INVESTING ACTIVITIES
Capital Expenditures			-$10.00K
YoY Change			0.0%
Acquisitions
YoY Change
Other Investing Activities	$7.680M	-$45.78M	$6.300M
YoY Change	4.49%	-703.16%	457.52%
Cash From Investing Activities	$7.680M	-$45.78M	$6.290M
YoY Change	4.49%	-703.37%	456.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$16.10M	$125.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.00K	$125.4M	-870.0K
YoY Change
NET CHANGE
Cash From Operating Activities	-12.65M	-11.20M	-10.17M
Cash From Investing Activities	7.680M	-$45.78M	6.290M
Cash From Financing Activities	30.00K	$125.4M	-870.0K
Net Change In Cash	-4.940M	68.41M	-4.750M
YoY Change	-166.94%	3315.33%	39.71%
FREE CASH FLOW
Cash From Operating Activities	-$12.65M	-$11.20M	-$10.17M
Capital Expenditures			-$10.00K
Free Cash Flow			-$10.16M
YoY Change			124.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001566044
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22977998	shares
CY2018Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	Menlo Therapeutics Inc.
CY2018Q1	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018Q1	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017Q4	mnlo	Accrued Clinicaland Development Expenses AccruedClinicalandDevelopmentExpenses	2250000	USD
CY2018Q1	mnlo	Accrued Clinicaland Development Expenses AccruedClinicalandDevelopmentExpenses	2506000	USD
CY2017Q4	mnlo	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	60958000	USD
CY2018Q1	mnlo	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	176268000	USD
CY2017Q4	mnlo	Cashand Cash Equivalentsand Availableforsale Securities Accumulated Gross Unrealized Gainbefore Tax CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax	0	USD
CY2018Q1	mnlo	Cashand Cash Equivalentsand Availableforsale Securities Accumulated Gross Unrealized Gainbefore Tax CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax	0	USD
CY2017Q4	mnlo	Cashand Cash Equivalentsand Availableforsale Securities Accumulated Gross Unrealized Lossbefore Tax CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax	51000	USD
CY2018Q1	mnlo	Cashand Cash Equivalentsand Availableforsale Securities Accumulated Gross Unrealized Lossbefore Tax CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax	202000	USD
CY2017Q4	mnlo	Cashand Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	61009000	USD
CY2018Q1	mnlo	Cashand Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	176470000	USD
CY2017Q1	mnlo	Depreciation Depletionand Amortization Excluding Amortizationof Discountsand Premiums DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums	2000	USD
CY2018Q1	mnlo	Depreciation Depletionand Amortization Excluding Amortizationof Discountsand Premiums DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums	5000	USD
CY2017Q1	mnlo	Increase Decreasein Prepaid Expensesand Other Current Assets IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets	179000	USD
CY2018Q1	mnlo	Increase Decreasein Prepaid Expensesand Other Current Assets IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets	-75000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2462000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3501000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	786000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	234000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-47000	USD
CY2018Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	123000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6355952	shares
CY2017Q4	us-gaap	Assets Assets	66867000	USD
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5298593	shares
CY2018Q1	us-gaap	Assets Assets	180479000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	63861000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	159658000	USD
CY2017Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22977998	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3559000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3174000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-51000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-202000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2207000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	237749000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	316000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	822000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8155676	shares
CY2018Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	0	investment
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4026000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6029000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10206000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78527000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2003000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	68321000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	55000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5298593	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22977998	shares
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5478000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12808000	USD
CY2017Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2018Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	109327000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1796000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1796000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	6735000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	6286000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.08
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.72
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1108000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	470000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1012000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2697000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-303000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1039000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-552000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	278000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-385000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-449000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-449000	USD
CY2017Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	125000	USD
CY2018Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-88000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-66000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	85000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-13000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	4000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	81000	USD
CY2018Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	563000	USD
CY2018Q1	us-gaap	Investments And Cash InvestmentsAndCash	176600000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	14574000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	14777000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66867000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	180479000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7817000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8471000	USD
CY2017Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	449000	USD
CY2018Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	497000	USD
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	2978000	USD
CY2018Q1	us-gaap	Long Term Investments LongTermInvestments	20713000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125389000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7587000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45778000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5584000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11290000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-5474000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-12657000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5474000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12657000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	6004000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	13717000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5555000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	24033000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3587000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	72778000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	125389000	USD
CY2017Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	14615000	USD
CY2018Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	22900000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	1200000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13220000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1341000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	173000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	675000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	493000	USD
CY2017Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	58000	USD
CY2018Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	225000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	201000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	198000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	83000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-151000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	22000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20000	USD
CY2017Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	8228000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3574000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	4100000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4992000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11020000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59191000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71848000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	316000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	822000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6772	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5600	shares
CY2018Q1	us-gaap	Short Term Investments ShortTermInvestments	77310000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-57034000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	165702000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5071721	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17583377	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	208337	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	85225000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2506926	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2505754	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.50
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.57
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.01
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	31.58
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M15D
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M29D
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	49295000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	125897	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	5280058	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	17709274	shares
CY2018Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Formation and Business of the Company</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Menlo Therapeutics Inc., or the “Company”, is a late‑stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as psoriasis and prurigo nodularis, as well as for the treatment of refractory chronic cough, a cough that persists for at least eight weeks despite treatment of any identified underlying cause. The Company believes that its product candidate, serlopitant, a highly selective once‑daily, oral small molecule inhibitor of the neurokinin 1</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, or NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1 </sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">receptor, has the potential to significantly alleviate itch and cough symptoms. Pruritus associated with psoriasis and prurigo nodularis, as well as refractory chronic cough, each represents a significant patient need. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company was incorporated in Delaware in October 2011. Since commencing operations, the Company has devoted substantially all of its resources to developing its product candidate, serlopitant, including conducting clinical trials and providing general and administrative support for these operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Initial Public Offering</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2018, the Company completed its initial public offering (“IPO”) of shares of its common stock, pursuant to which the Company issued </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of common stock, which includes </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares issued pursuant to the over-allotment option granted to its underwriters, and received net proceeds of approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$125.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, after deducting underwriting discounts, commissions and offering expenses. In connection with the completion of the Company's IPO, all shares of convertible preferred stock converted into </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9,629,405</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of common stock.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Since inception, the Company has incurred losses and negative cash flows from operations. For the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">three</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> months ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 31, 2018</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, the Company incurred a net loss of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$12.7 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and used $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of cash in operations. As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 31, 2018</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, the Company had cash, cash equivalents and investments of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$176.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and an accumulated deficit of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$71.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. Management plans to finance operations through equity or debt financing arrangements, and/or third‑party collaboration funding. There can be no assurances that, in the event that the Company requires additional financing, such financing will be available on terms which are favorable to the Company, or at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company believes that its existing cash, cash equivalents and investments as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 31, 2018</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> will provide sufficient funds to enable it to meet its obligations for at least the next twelve months.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Preparation of financial statements in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, stock‑based compensation expense, the resolution of uncertain tax positions and valuation allowance and accruals for research and development costs. Management bases its estimates on historical experience on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-18-006412-index-headers.html	Edgar Link	pending
0001628280-18-006412-index.html	Edgar Link	pending
0001628280-18-006412.txt	Edgar Link	pending
0001628280-18-006412-xbrl.zip	Edgar Link	pending
exhibit311.htm	Edgar Link	pending
exhibit312.htm	Edgar Link	pending
exhibit321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mnlo-20180331.xml	Edgar Link	completed
mnlo-20180331.xsd	Edgar Link	pending
mnlo-20180331_cal.xml	Edgar Link	unprocessable
mnlo-20180331_def.xml	Edgar Link	unprocessable
mnlo-20180331_lab.xml	Edgar Link	unprocessable
mnlo-20180331_pre.xml	Edgar Link	unprocessable
mnlo033118q110-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VYNE
VYNE Therapeutics Inc. Stock $vyne

2018 Q2 Form 10-Q Financial Statement

#000162828018006412 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE VYNE Therapeutics Inc. Stock $vyne

2018 Q2 Form 10-Q Financial Statement

#000162828018006412 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE
VYNE Therapeutics Inc. Stock $vyne